

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# COVID-19 Pandemic: Is Africa Different?

Ebun L. Bamgboye, M.B.B.S., F.W.A.C.P., F.R.C.P., Jesutofunmi A. Omiye, M.B.B.S., Oluwasegun J. Afolaranmi, M.B.B.S., Mogamat Razeen Davids, M.B.Ch.B., F.C.P., M.Med., Ph.D., Elliot Koranteng Tannor, M.D., M.Phil., M.B.A., Shoyab Wadee, M.B.B.Ch., M.Med., F.C.P., Abdou Niang, M.D., Anthony Were, M.B.Ch.B., M.Med., F.R.C.P., M.D., Saraladevi Naicker, M.B.Ch.B., Ph.D., F.R.C.P.

Abstract: COVID-19 has now spread to all the continents of the world with the possible exception of Antarctica. However, Africa appears different when compared with all the other continents.

The absence of exponential growth and the low mortality rates contrary to that experienced in other continents, and contrary to the projections for Africa by various agencies, including the World Health Organization (WHO) has been a puzzle to many. Although Africa is the second most populous continent with an estimated 17.2% of the world's population, the continent accounts for only 5% of the total cases and 3% of the mortality. Mortality for the whole of Africa remains at a reported 19,726 as at August 01, 2020.

The onset of the pandemic was later, the rate of rise has been slower and the severity of illness and case fatality rates have been lower in comparison to other continents. In addition, contrary to what had been documented in other continents, the occurrence of the renal complications in these patients also appeared to be much lower.

This report documents the striking differences between the continents and within the continent of Africa itself and then attempts to explain the reasons for these differences.

It is hoped that information presented in this review will help policymakers in the fight to contain the pandemic, particularly within Africa with its resourceconstrained health care systems.

Keywords: COVID-19■Africa■Acute kidney injury■Pandemic■APOL1■ COVAN■SARS-COV-2 virus■Chronic kidney disease

Author affiliations: Ebun L. Bamgboye, St Nicholas Hospital, Lagos, Nigeria; Jesutofunmi A. Omiye, St Nicholas Hospital, Lagos, Nigeria; Oluwasegun J. Afolaranmi, St Nicholas Hospital, Lagos, Nigeria; Mogamat Razeen Davids, Division of Nephrology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa; Eliot Koranteng Tannor, Renal Unit, Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana; Shoyab Wadee, Wits Donald Gordon Medical Centre, University of the Witwatersrand, Johannesburg, South Africa; Abdou Niang, Dalal Jamm Hospital, Dakar Cheikh A. Diop University, Senegal; Anthony Were, Department of Medicine, East African Kidney Institute, College of Health Sciences, University of Nairobi, Kenya; Saraladevi Naicker, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Correspondence: Ebun L. Bamgboye, M.B.B.S., F.W.A.C.P., F.R.C.P., St Nicholas Hospital, 57 Campbell Street, Lagos Island, Lagos, Lagos, Nigeria. Fax: +234-1-2633915. email: ebamgboye@saintnicholashospital.com

© 2020 by the National Medical Association. Published by Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.jnma.2020.10.001

## INTRODUCTION

OVID-19, a novel disease caused by the SARS-COV-2 virus<sup>1</sup> was declared by the World Health Organization (WHO) as a public health emergency of international concern on January 30, 2020 and as a global pandemic on the 11 March 2, 020.<sup>2</sup> First noted in Wuhan in the Hubei province of China in December 2019, it has now spread to all the continents except Antarctica.<sup>3</sup> Every country in the world, with the possible exception of North Korea and Turkmenistan, has documented confirmed cases with a spiraling increase in COVID-19 related mortality and an excess of overall mortality compared to previous years.<sup>4</sup>

Although COVID-19 manifests primarily as a respiratory tract infection, there have been many reports of renal involvement, more so in the severe forms of the disease.<sup>5,6</sup> Patients with chronic kidney disease (CKD) are amongst those at the highest risk for developing severe disease. This is over and above other recognized risk factors like hypertension, diabetes, chronic lung disease, and cancers, which are common comorbidities and often coexist with CKD.

Patients on maintenance haemodialysis (HD) are at particular risk, given the need to come into dialysis centres for their treatment sessions. The enclosed spaces of most dialysis units with centralized, recycled air-conditioning and the length of time necessary for haemodialysis further compounds this risk. Patients with kidney transplants need to use immunosuppressive agents which increases their risk of acquiring the illness and of progression to severe disease.

Acute kidney injury (AKI) is one of the more common complications of severe COVID-19 and studies have reported an incidence as high as 46% amongst hospitalized patients, with it being one of the major reasons for mortality in these patients.<sup>6</sup> Recent reports have also suggested a possible association between high-risk APOL1 genotype, common in peoples of African descent, and the increased risk of kidney disease in COVID-19.<sup>7</sup> Reports of collapsing glomerulopathy associated with COVID-19 in patients of African ancestry who are carriers of APOL1 risk variants have also been described and the name COVID-19-associated nephropathy (COVAN) for the condition has been proposed.<sup>8</sup>

These challenges are superimposed on nephrology practice in a continent that has limited resources and

capacities to deal with renal patients even preceding the ongoing pandemic. Africa is the world region with the lowest density of nephrologists at 3.6 per million population (pmp), and nine of the ten countries with the lowest nephrologist densities are from the Africa region. Many countries have no trained nephrologists and many that do, have very low numbers with few dialysis units often restricted to the urban centres. Peritoneal dialysis is not widely available as the fluids are not manufactured locally and the cost of importation puts this beyond the reach of most patients as costs are often borne out-of-pocket by the patients themselves.<sup>9-13</sup>

Against this background, the African Association of Nephrology (AFRAN), developed COVID-19 guidelines to guide nephrologists in the continent on measures to be taken by nephrology practitioners in the care of our regular patients during this pandemic and also in the management of patients developing the renal complications of COVID-19.<sup>14</sup> During the discussions leading to the production of the guidelines, local experiences and insights were shared by members of the expert committee from the different countries represented on the committee. These discussions prompted AFRAN to conduct a more formal survey to document the experience of COVID-19 in different member countries. This report also summarizes the results of the survey and reflects on the reasons for some of the apparent differences in the pandemic between African countries and those in other parts of the world.

## **METHODS**

Two sets of data were collected for this study. The first included data to allow comparisons between Africa and other regions as well as comparisons within Africa itself. We also collected data on variables that could explain the apparent differences in COVID-19 case numbers, mortality, and tests in Africa, compared to other parts of the world. For all data sets, publicly available data was gathered up until August 01, 2020. Data on COVID-19 cases, mortality, and test was retrieved from the Worldometer website (http://www.worldometers.info/coronavirus/), Worldometer is a trusted data aggregator site that retrieves timely data from official websites and social media accounts of ministries of health, government institutions, and official press briefings.<sup>15</sup> The African data was augmented with information from the African Centres for Disease Control (http://africacdc.org/covid-19/) and official reports from the Disease Control Centres of various African countries.

Data on environmental variables i.e. humidity, temperature, and UV index was obtained from Weather online (https://www.weatheronline.co.uk/), a site that provides global meteorological data.<sup>16</sup> This source has also been used in previous studies on temperature and coronavirus cases.<sup>17,18</sup> The Human Development Index (HDI) data was retrieved from the United Nations Development Program (UNDP) 2019 Human development report. Flights data was accessed from the International Civil Aviation Organization, which publishes civil aviation statistics on air transport. Additionally, data on healthcare access and quality index (HAQI) was sourced from the Lancet Global Burden of Disease Study.<sup>19</sup> Furthermore, data on population density and diabetes prevalence was accessed from Worldometer and the International Diabetes Federation (IDF).<sup>15,20</sup>

The second set of data was collected via a survey amongst physicians in various countries in Africa in the process of developing the AFRAN COVID-19 guidelines. An electronic (Google Forms) questionnaire was sent out on a WhatsApp forum populated by nephrologists from different countries in Africa. Questions focused on the availability of nephrology resources in the countries of the various respondents and on their experience with managing cases of COVID-19 with particular focus on the renal complications of the disease.

Case numbers, mortality, number of tests performed, and demographic data were summarized and compared by continents, regions, and countries within the continent of Africa. Also, we compared all African countries to the top 10 worst-hit COVID-19 countries. Scatter plots were used to visualize the data and correlation coefficients were calculated to identify the strengths of the relationships between variables. The data analysis tool on the Google Forms platform was used to summarize the survey responses.

## RESULTS

Africa accounts for 17.2% of the world's population, but only about 5% of the total COVID-19 cases diagnosed and 3% of the related mortality (Figure 1).

The number of cases per million population (pmp) globally is 2,278, with South America (9549 pmp), North America (9,331) and Europe (3,842) the most affected regions, while Africa has a lower rate of 695 pmp (Figure 2). The case fatality rates have been 3.9% worldwide, 7.1% in Europe, 4.0% in North America, 3.5% in South America and 2.1% in Africa.

Furthermore, as shown in Figure 3, the values also vary considerably within the various countries in the African continent, although this might be related to differences in the number of tests performed (Table 1).

South Africa and Egypt have reported the most cases. Importantly, these countries are amongst the countries at the top of tests done which is a critical factor in determining the number of confirmed cases. All the countries



surveyed employed the rt-PCR method for diagnosis and many have experienced constraints with obtaining the necessary reagents. South Africa, Morocco, Ethiopia and Ghana however stand out prominently in terms of the number of tests done thus far. Ghana has used pooled samples for screening suspected cases with separate tests done for only the positive pooled samples.

The experience shared by African nephrologists has revealed that most of the cases have been completely asymptomatic or mildly symptomatic, with very few patients requiring intensive care. The first set of patients managed in Nigeria were mostly asymptomatic and none required intensive care.<sup>21</sup>

This has also reflected in the prevalence of the renal complications of COVID-19 and the need for renal replacement therapy (RRT). The responses from the survey have indicated a paucity of cases requiring RRT, with



61% of respondents having no cases in their country requiring RRT. Countries with more developed healthcare systems like Egypt and South Africa had a greater number of cases. Approximately 90% of respondents noted that haemodialysis was available as a means of RRT.

The survey also confirmed the poor state of nephrology care in the continent with many countries having limited numbers of nephrologists, few dialysis centres and very few dialysis machines. The median number of dialysis centres and nephrologists among the respondents were 25 and 28 respectively.

The public health response of several countries consisted of a containment policy involving the isolation of all positively diagnosed cases at isolation centres. Unfortunately, quite a number of these isolation centres lacked the capacity to perform dialysis as indicated by 28% of the survey respondents, with the consequences of avoidable mortality. Some centres with limited capacity had only a single dialysis unit.

There are regional differences within the continent as regards the severity of cases and the outcomes, with the countries in North Africa having the worst outcomes. The case fatality rate is 3.1% for North Africa, 1.4% for West Africa, 1.6% for South Africa, 1.3% for East Africa and 1.3% for Central Africa. South Africa and Egypt account for 63% of all African cases and for 65% of the mortality. These two countries along with Nigeria, the third ranked in terms of numbers, are also the three strongest economies on the continent. North Africa particularly appears to have the worst statistics in Africa, even though their numbers



represent 17% of total cases, they constitute 34% of mortality.

# DISCUSSION

Several reasons have been adduced for this unexpected pattern of illness being seen in Africa.

## Seeding effect

Given that COVID-19 reached countries in Africa by importation from Asia, Europe, and America, the onset of the disease in most countries was much later than was experienced in other continents. Of the 54 countries in Africa, 4 reported their first case in February, 42 in March, 7 in April, and 1 in May. This of course suggests that many of these countries are still experiencing the early stages of the pandemic.

The number of cases in the early stages of the pandemic was directly proportional to the number of international flights into African countries. The busiest international airports in the continent are located in South Africa which also has the highest numbers on the continent, followed by Egypt which is also second in case numbers (Figure 4A). Countries with infrequent business and tourism contacts with other continents are those with the lowest numbers (Figure 4B). The few countries to buck this trend were countries like Kenya and Ethiopia whose airports serve as hubs for several countries on the continent and many international travelers pass through their airports and not actually into these countries.

Many African countries with previous experience of managing other epidemic infectious diseases like Ebola, Tuberculosis, and Lassa fever closed down their airports to international travels much earlier than had been done in other continents. Prior to the closure, many commenced disease surveillance activities and contact tracing at the airports, again much earlier than was done in many other countries outside the continent. All of these factors limited the number of cases "seeded" into African countries delaying the outset and the subsequent growth in numbers thereby "flattening the curve" in many of these countries.

## Testing capacity

This is another major potential reason for the relatively lower numbers of cases on the continent. The number of positive cases reported is driven by the number of rt-PCR tests performed. The top five testing countries in the world (as of August 01, 2020) were China -90 million, the USA- 50 million, Russia- 26 million, India- 15 million, and the UK- 13 million. In contrast, the top four countries in Africa were South Africa with 2.9 million tests, Morocco with 1.2 million, Ethiopia with 422,000, and Ghana with 391,000 tests done as at the same date. Within the continent, the top testing countries were also the countries with the highest number of cases. Many countries have been Table 1. Shows dataset of the top 10 most impacted COVID-19 countries and all African countries.

Country	Tests pmp	Cases pmp	Total cases	Deaths pmp	Total deaths	Case fatality
USA	176,923	14,324	4,705,889	475	156,747	3.3
Brazil	61,575	12,580	2,666,298	436	92,568	3.5
India	13,636	1268	1,697,054	27	36,551	2.1
Russia	192,966	5793	839,981	96	13,963	1.7
Mexico	7628	3291	424,637	362	46,688	11
Peru	70,231	12,564	407,492	582	19,021	4.6
Chile	84,893	18,696	355,667	498	9457	2.7
Spain	142,834	7178	335,602	608	28,445	8.5
Iran	29,221	3648	304,204	202	16,766	5.5
UK	235,878	4475	303,181	680	46,119	15.2
South Africa	49,850	8307	493,183	135	19,726	1.6
Egypt	1317	918	94,078	47	8005	5.1
Nigeria	1321	209	43,151	4	879	2
Ghana	12,575	1141	35,501	6	182	0.5
Algeria	NA	705	30,394	28	1210	4
Morocco	33,897	677	24,322	10	353	1.5
Kenya –	5541	397	20,636	6	341	1.7
Ethiopia	3667	156	17,530	0	274	1.6
Cameroon	5602	649	17,255	15	391	2.3
Cote d'Ivoire	3810	610	16,047	4	102	0.6
Sudan	9	267	11,644	17	746	6.4
Madagascar	1469	406	10,868	4	106	1
Senegal	6426	613	10,232	12	205	2
DRC	NA	101	9070	2	215	2.4
Gabon	33,736	3297	7352	22	49	0.7
Guinea	1095	555	7308	3	46	0.6
Mauritania	12,289	1354	6310	34	157	2.5
Zambia	4511	338	5963	8	151	2.5
Djibouti	57,343	5140	5084	59	58	1.1
Equatorial Guinea	31,542	3428	4821	59	83	1.7
CAR	6099	954	4608	12	59	1.3
Malawi	1544	213	4078	6	114	2.8
Zimbabwe	8806	213	3169	5	67	2.1
Libya	7274	526	3621	11	74	2
Somalia	NA	202	3212	6	93	2.9
Congo	NA	579	3200	10	54	1.7
Eswatini	17,889	2280	2648	35	41	1.5
Mayotte	47,565	10,838	2962	143	39	1.3
Mali	1118	125	2535	6	124	4.9

continued...

Country	Tests pmp	Cases pmp	Total cases	Deaths pmp	Total deaths	Case fatality
Cabo Verde	74,816	4457	2451	41	23	1
South Sudan	1075	207	2322	4	46	2
Namibia	10,321	874	2129	4	10	0.5
Rwanda	20,299	156	2022	0.4	5	0.2
Guinea-Bissau	761	1005	1981	13	26	1.3
Mozambique	1843	60	1864	0.4	11	0.6
Sierra Leone	NA	228	1823	8	67	3.7
Benin	7069	149	1805	3	36	2
Tunisia	8104	130	1535	4	50	3.3
Liberia	NA	235	1186	15	75	6.3
Uganda	5951	26	1154	0.07	3	0.3
Angola	1924	35	1148	2	52	4.5
Burkina Faso	NA	53	1106	3	53	4.8
Niger	373	47	1134	3	69	6.1
Тодо	5126	113	941	2	19	2
Chad	NA	57	936	5	75	8
Sao Tome & Principe	13,295	3969	871	68	15	1.7
Botswana	29,051	341	804	0.8	2	0.2
Lesotho	3481	327	604	6	13	2.2
Reunion	39,537	741	660	4	4	0.6
Tanzania	NA	9	509	0.4	21	4.1
Gambia	2006	206	498	4	9	1.8
Burundi	1205	33	387	0.08	1	0.3
Mauritius	161,394	270	344	8	10	2.9
Eritrea	NA	79	279	0	0	0
Comoros	NA	443	378	8	7	1.9
Seychelles	NA	1159	114	0	0	0
Western Sahara	NA	17	10	2	1	10

limited by the costs of these tests and the non-availability of the necessary equipment, reagents, and trained personnel. Ghana notably has done many more tests per million of its population by pooling samples, thus testing more patients with each kit deployed. Antibody testing in several countries suggests that many cases might have been missed by the paucity of tests carried out in the continent. Many of these tests suggest that as much as 10%-20% of the population in some of these countries might have already contracted and recovered from the disease. In fact, preliminary results from a study from the Western Cape in South Africa revealed a seroprevalence of antibodies in 40% of antenatal screening specimens and routine monitoring blood tests done for HIV positive ante-natal clinic patients.<sup>21</sup> It is also possible that many deaths attributed to other reasons in the absence of testing might have been due to COVID-19.

#### Population and population density

The population density in Africa is much lower than many of the countries in other continents. The disease spreads quicker and more easily in crowded, enclosed, and noisy spaces. Many communities on the continent are rural and widely dispersed, which slows the spread of the virus. The



"hotspots" in most countries are the crowded major cities like Lagos in Nigeria (responsible for over 40% of cases), Johannesburg and Cape Town in South Africa, Nairobi in Kenya, and Cairo in Egypt. Within these cities, the greatest numbers are seen in crowded communities such as Kosofe and Alimosho in Lagos.



The institution of lockdown measures early in the pandemic has also served to limit the spread of the disease. Countries like Rwanda and Senegal which implemented strict and efficient measures were able to limit the spread even better



than surrounding countries in their sub-regions. Many of these countries, following the economic distress caused by these lockdown measures, have had to relax some of these measures with the consequence of, in some cases, rising numbers.

#### Power of youth

Africa is the youngest continent on the planet; the median age of the countries in Sub-Saharan Africa is 18 years. This is in comparison to Europe for instance where the median age is 37 years. Individuals in Europe over the age of 65 years constitute 20.8% of the population, whilst that of sub-Saharan Africa is 3%. Younger individuals are 4 times less likely to acquire the illness and when they do, they seldom develop severe symptoms or die from the illness. Within the continent as well, countries with slightly older populations like Egypt and South Africa are also the ones with the highest numbers and the greater case fatality rates (Figure 5).

Older individuals are also the ones more likely to have the various co-morbidities that have been associated with severe disease and the risk of mortality. These include obesity, type 2 diabetes, and malignancies. The prevalence of these conditions is greatest in the countries of the Maghreb and South Africa all of which have the highest



case numbers and the worst CFR on the continent (Figures 6 and 7). In Nigeria, 75% of patients admitted at the isolation centres had no comorbidities whilst in South Africa, 64% had at least one comorbidity. This could partly explain the larger numbers and higher mortality observed in South Africa.

The cultural practice of caring for elderly relatives at home as opposed to using care facilities may also be a major factor. In Europe and the USA, these care homes were major centres for transmission of COVID-19 with the resultant heightened mortality.

Age might also be relevant in the Vitamin D related factor as younger individuals are more efficient in the production of Vitamin D from sunlight and are more likely to be ambulant and exposed to the sun for this to happen. People living near the equator get more UVB light from the sun and thus generally have higher serum Vitamin D levels than those living farther away. Healthy levels of Vitamin D give patients with COVID-19 a survival advantage by helping them avoid the cytokine storm. Some preliminary studies have demonstrated that Vitamin D status and sun exposure are important factors to consider for reducing the rates of transmission, infection, and severity of illness.<sup>22,23</sup>

## Exposure to previous infections

There are speculations of the possible relative resistance to the virus with resultant milder presentation and much lower mortality being observed on the continent. There is a hypothesis that exposure to similar coronaviruses in the past may have conferred relative immunity to patients on the continent. Coronavirus cross-reactive antibodies may contribute to a low transmission rate and reduced severity of disease associated with SARS-COV-2 through crossneutralization and rapid clearance.<sup>24</sup>

The heightened immunity obtained from exposure to previous infections like malaria and other ongoing endemic infections, like Tuberculosis and HIV, has been speculated as a possible reason for the milder presentation of the COVID-19 in Africa.

Ongoing vaccination for tuberculosis using the BCG vaccine has also been speculated to be a factor in protecting vaccinated individuals from acquiring the illness and when they do, from the severity of disease and mortality. Most countries in Africa continue to vaccinate their citizens against pulmonary tuberculosis with BCG, as the disease remains endemic in various countries on the continent. Countries in Europe with later discontinuation of BCG vaccination also all seem to have relatively fewer cases and



Figure 8. (A) Human development index and deaths from COVID-19 per million population (Log scale). (B) HAQ index and cases of COVID-19 per million

milder illness than their surrounding neighbours. Although we could not find a correlation with BCG vaccination and the number of coronavirus cases, some studies have shown BCG to be protective against severe cases of the illness.<sup>25,26</sup>

#### Human development and healthcare quality

A correlation has been observed between the Human Development Index (HDI) and the numbers of cases and case fatality rate. Countries with higher HDI have higher numbers and worse outcomes (Figure 8A). Another surrogate of healthcare development, the Healthcare Access and Quality (HAQ) index showed quite a similar pattern (Figure 8B). The Pearson correlation coefficients for HDI and HAQ, against COVID-19 cases pmp were noted to be 0.69 and 0.51 respectively.

## Sunlight, UV-light, heat and humidity

Some studies have suggested that temperatures in excess of 27 °C, ultra-violet rays associated with sunlight and humidity all tend to have negative effects on the survival of the virus.<sup>18</sup> We could not demonstrate this for African countries. However, the rise in numbers in the southern part of the continent currently experiencing their winter season and the relatively lower numbers and mortality in countries closer to the equator with higher temperatures and higher intensity of UV-light might be in keeping with these speculations.

# CONCLUSION

Despite weaker health care facilities and systems, the growth of cases in Africa has defied most predictions and has remained geometric and not exponential. Available data and statistics continue to reflect consistently lower numbers than those in other continents except for Oceania.

The severity of presentation has also remained relatively mild and the anticipated overwhelming of the health systems, including the renal services of the various countries on the continent has not been seen. Mortality and case fatality rates have been a fraction of what had been predicted.

This is however not a reason to be complacent as for many African countries, these are still early days in the pandemic and a change in the Pattern may yet occur as the numbers continue to rise. It has taken six months to reach the first 500,000 cases but less than two months to cross the million cases mark on the continent.

# REFERENCES

 A novel coronavirus from patients with pneumonia in China, 2019 | NEJM [Internet]. Available from: https://www.nejm.org/ doi/full/10.1056/nejmoa2001017. Accessed August 31, 2020.

- WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. Available from: https:// www.who.int/dg/speeches/detail/who-director-general-s-openingremarks-at-the-media-briefing-on-covid-19—11-march-2020. Accessed August 31, 2020.
- 3. WHO coronavirus disease (COVID-19) Dashboard [Internet]. Available from: https://covid19.who.int. Accessed August 31, 2020.
- Excess deaths associated with COVID-19 [Internet]. Available from: https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess\_ deaths.htm, (2020). Accessed August 31, 2020.
- Huang, C., Wang, Y., Li, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*, 395(10223), 497–506.
- Cheng, Y., Luo, R., Wang, K., et al. (2020). Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*, 97(5), 829–838.
- Larsen, C. P., Bourne, T. D., Wilson, J. D., Saqqa, O., & Sharshir, M. A. (2020). Collapsing glomerulopathy in a patient with COVID-19. *Kidney Int Rep*, 5(6), 935–939.
- Velez, J. C. Q., Caza, T., & Larsen, C. P. (2020). COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol, 1–3.
- Ashuntantang, G., Osafo, C., Olowu, W. A., et al. (2017). Outcomes in adults and children with end-stage kidney disease requiring dialysis in Sub-Saharan Africa: a systematic review. Lancet Glob Health, 5(4), e408–e417.
- Niang, A., & Lemrabott, A. T. (2020). Global dialysis perspective: Senegal. *Kidney360*, 1(6), 538–540.
- Bello, A., Levin, A., Lunney, M., et al. (2019). ISN Global Kidney Health Atlas 2019. International Society of Nephrology.
- Osman, M. A., Alrukhaimi, M., Ashuntantang, G. E., et al. (2018). Global nephrology Opinion paper workforce: gaps and opportunities toward a sustainable kidney care system. *Kidney Int Suppl*, 8(2), 52–63.
- Bamgboye, E. (2016). The challenges of ESRD care in developing economies: sub-Saharan African opportunities for significant improvement. *Clin Nephrol*, 86(13), 18–22.
- Elsayed, H. M., Wadee, S., Zaki, M. S., et al. (2020). Guidelines for the prevention, detection and management of the renal complications of COVID-19 in Africa. *Afr J Nephrol*, 23(1), 109–126.
- Coronavirus update (live): 17,757,513 cases and 682,998 deaths from COVID-19 virus pandemic - worldometer [Internet]. Available from: https://web.archive.org/web/202008 01032838/https://www.worldometers.info/coronavirus/#c-all% 22, (2020). Accessed August 31, 2020.
- World weather | world weather online [Internet]. Available from: https://www.worldweatheronline.com/country.aspx. Accessed September 6, 2020.

- Ibekwe, P. U., & Ukonu, B. A. (2019). Impact of weather conditions on atopic dermatitis prevalence in abuja, Nigeria. J Natl Med Assoc, 111(1), 88–93.
- Gunthe, S. S., Swain, B., Patra, S. S., & Amte, A. (2020). On the global trends and spread of the COVID-19 outbreak: preliminary assessment of the potential relation between locationspecific temperature and UV index. J Public Health, 1–10.
- Barber, R. M., Fullman, N., Sorensen, R. J. D., et al. (2017). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet*, 390(10091), 231–266.
- Global diabetes data report 2010 2045 [Internet]. Available from: https://www.diabetesatlas.org/data/. Accessed September 6, 2020.
- Spotlight, A. B. (2020). Maverick citizen: spotlight: Covid-19: high prevalence found in Cape Town antibody study [Internet]. Daily Maverick. Available from: https://www. dailymaverick.co.za/article/2020-09-04-covid-19-high-prevalencefound-in-cape-town-antibody-study/. Accessed September 14, 2020.

- Daneshkhah, A., Agrawal, V., Eshein, A., Subramanian, H., Roy, H. K., & Backman, V. (2020). The possible role of Vitamin D in suppressing cytokine storm and associated mortality in COVID-19 patients [Internet]. *Infectious Diseases*. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.08.20058578. Accessed September 14, 2020.
- Lau, F. H., Majumder, R., Torabi, R., et al. (2020). Vitamin D insufficiency is prevalent in severe COVID-19 [Internet]. Infectious Diseases. Available from: http://medrxiv.org/lookup/doi/1 0.1101/2020.04.24.20075838. Accessed September 14, 2020.
- 24. Sariol, A., & Perlman, S. (2020). Lessons for COVID-19 immunity from other coronavirus infections. *Immunity*, 53(2), 248–263.
- Escobar, L. E., Molina-Cruz, A., & Barillas-Mury, C. (2020).
  BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A, 117(30), 17720–17726.
- Gursel, M., & Gursel, I. (2020). Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic? Med Hypotheses. Available from: https://www. ncbi.nlm.nih.gov/pmc/articles/PMC7136957/. Accessed September 7, 2020.